...
机译:阵发性夜间血红蛋白的补体C5抑制剂Crapimab
Univ Hosp Essen Dept Hematol West German Canc Ctr Essen Germany;
Osaka Univ Grad Sch Med Osaka Japan;
Semmelweis Egyet I Sz Belgyogyaszati Klin Budapest Hungary;
Semmelweis Egyet I Sz Belgyogyaszati Klin Budapest Hungary;
Rheinisch Westfal Hsch RWTH Aachen Univ Hosp Dept Hematol Oncol Hemostaseol &
Stem Cell Transp;
Seoul Natl Univ Hosp Clin Res Inst Seoul South Korea;
Kaposi Mor Oktato Korhaz Kaposvar Hungary;
Tohoku Univ Hosp Sendai Miyagi Japan;
Tokyo Med Univ Dept Internal Med 1 Hematol Div Tokyo Japan;
Yonsei Univ Severance Hosp Coll Med Seoul South Korea;
Univ Tsukuba Dept Med Sci Fac Med Tsukuba Ibaraki Japan;
Univ Hosp Ulm Inst Transfus Med Ulm Germany;
Fdn Policlin Univ A Gemelli Ist Ricovero &
Cura C Rome Italy;
NTT Med Ctr Tokyo Tokyo Japan;
Hop St Louis Serv Hematol Greffe Ctr Reference Aplasie Medullaire Hemolyse Paroxys Paris France;
Hop St Louis Ctr Invest Clin Paris France;
Roche Innovat Ctr Roche Pharma Res &
Early Dev Basel Switzerland;
Roche Prod Ltd Welwyn Garden City England;
Roche Innovat Ctr Roche Pharma Res &
Early Dev Basel Switzerland;
Genentech Inc San Francisco CA USA;
Roche Prod Ltd Welwyn Garden City England;
Chugai Pharmaceut Tokyo Japan;
Roche Diagnost GmbH Penzberg Germany;
Roche Innovat Ctr Roche Pharma Res &
Early Dev Basel Switzerland;
Roche Innovat Ctr Roche Pharma Res &
Early Dev Basel Switzerland;
Genentech Inc San Francisco CA USA;
Roche Innovat Ctr Roche Pharma Res &
Early Dev Basel Switzerland;
Univ Paris Hop St Louis Ctr Reference Aplasie Medullaire HPN Serv Hematol Greffe Ctr Invest Clin;
机译:阵发性夜间血红蛋白的补体C5抑制剂Crapimab
机译:对临床和临床前阶段的C3-调理素靶向补体抑制剂治疗阵发性夜间血红蛋白尿症的评估表明,分子特征对于控制患病宿主细胞的补体活化至关重要
机译:阵发性夜间血红蛋鱼的第二代C5抑制剂
机译:补充特异性抑制剂的发展概述:阵发性夜间血红蛋白治疗的机会
机译:胶原蛋白,补体C3和C5在皮肤伤口愈合中的作用:在实验大鼠中的局部制剂,制备和体内评估
机译:Ravulizumab:一种新型的C5抑制剂用于治疗阵发性夜间血红蛋白尿
机译:Ravulizumab:一种新型C5抑制剂,用于治疗阵发性夜间血红蛋白